HC Wainwright set a $10.00 price objective on Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued to investors on Friday, TipRanks reports. The brokerage currently has a hold rating on the stock.
A number of other analysts have also commented on the company. Piper Jaffray Companies decreased their target price on Syros Pharmaceuticals from $24.00 to $18.00 in a research report on Thursday. JMP Securities decreased their target price on Syros Pharmaceuticals from $18.00 to $16.00 and set a market outperform rating for the company in a research report on Friday. ValuEngine raised Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday. Zacks Investment Research raised Syros Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, September 28th. Finally, BidaskClub raised Syros Pharmaceuticals from a hold rating to a buy rating in a research report on Friday. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $15.03.
Shares of Syros Pharmaceuticals stock opened at $6.74 on Friday. Syros Pharmaceuticals has a one year low of $5.17 and a one year high of $11.93. The firm has a market capitalization of $295.37 million, a price-to-earnings ratio of -3.53 and a beta of 1.61. The business has a 50-day simple moving average of $9.99 and a 200 day simple moving average of $8.23. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.11 and a quick ratio of 8.11.
In other Syros Pharmaceuticals news, Director Richard A. Young sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 14.80% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of SYRS. Bank of Montreal Can increased its holdings in Syros Pharmaceuticals by 11,319.2% during the 2nd quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock worth $27,000 after purchasing an additional 2,943 shares in the last quarter. A.R.T. Advisors LLC bought a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $119,000. Susquehanna International Group LLP bought a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $133,000. Algert Global LLC bought a new stake in Syros Pharmaceuticals during the 2nd quarter worth approximately $166,000. Finally, Bank of New York Mellon Corp increased its holdings in Syros Pharmaceuticals by 27.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 105,908 shares of the company’s stock worth $981,000 after purchasing an additional 22,658 shares in the last quarter. 82.08% of the stock is owned by hedge funds and other institutional investors.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.